Acquired immunodeficiency
Therapeutic area
Immunology
Rare disease
Yes
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Acquired immunodeficiency
- Alternative names
- acquired immunodeficiency
- Therapeutic area
- Immunology
- All therapeutic areas
- Immunology
- Severity
- Severe
- MONDO ID
- MONDO:0017769
- Parent condition
- MONDO:0005046
Related records
Broader conditions (4)
- Disease
- Disease by body system or component
- Human disease
- Immune system disorder
Narrower conditions (2)
- Acquired adult-onset immunodeficiency
- Good syndrome
Trials (3,020)
- 'Activity Pacing' in PLWH With Fatigue Symptoms.
- 'HI-4-TU' Study: Health Improvement for Teen Ugandans Study
- "OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
- "Switch Either Near Suppression Or THOusand"
- (Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC
- #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.
- 123I Radiolabeled 3BNC117
- 2-5 Intermittent Caloric Restriction in HIV
- 2-stage Cervical Cancer Screening in Botswana
- 2nd AC+: New Village Model
- 2NN & CHARM Long-Term Follow-up Study
- 3BNC117 and 10-1074 in ART-treated Individuals
- 3BNC117 and 10-1074 in HIV Uninfected Adults
- 3BNC117 and 10-1074 in HIV-infected Individuals
- 3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
- 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
- 3BNC117-LS First-in-Human Phase 1 Study
- 3TC (Lamivudine; GR109714X) Open-Label Program
- 4-Methylumbelliferone as a Treatment for Chronic HBV/HCV
- 90 DAYS: An Entertainment Education Intervention to Evaluate a Short Film About HIV Status Disclosure